News

Novartis announced new data from the MAXIMISE trial evaluating the efficacy and safety of Cosentyx (secukinumab) in the management of axial manifestations of psoriatic arthritis (PsA).…
Read More...

Harbour BioMed (HBM) and Erasmus MC, University Medical Center Rotterdam announced that they have signed a 10-year Memorandum of Understanding (MOU) to enable a broad range of joint…
Read More...

Swedish Orphan Biovitrum AB (publ) (Sobi) has signed an agreement to acquire, from Novimmune’s shareholders, a newly established company owning emapalumab and related assets, giving…
Read More...

Eton Pharmaceuticals, Inc. announced that the Company has entered into an agreement with Aucta Pharmaceuticals, Inc to acquire U.S. marketing rights for ET-105. ET-105 is an…
Read More...

SAGA Diagnostics AB, a precision oncology genomics testing company focused on ultrasensitive monitoring of cancer patients using blood samples and other liquid biopsies and tissues,…
Read More...

AptarGroup, Inc. announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of…
Read More...

BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, announced it has licensed a new set of bacterial targets from JSR Corporation, for the…
Read More...

Roche announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan…
Read More...

GT Apeiron Therapeutics, a novel biotechnology company, was launched with the backing from GT Healthcare and associated investors. The company also entered into a drug discovery…
Read More...

Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy in…
Read More...

Genmab A/S announced that it has entered into an exclusive worldwide license and option agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize HexaBody-CD38, a…
Read More...

Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, and Zai Lab Ltd., a China and U.S.-based innovative…
Read More...

Genentech announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Polivy (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan…
Read More...

Hoth Therapeutics, a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis-also known as eczema-as well as…
Read More...

Merck, known as MSD outside the United States and Canada, announced that it has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held biopharmaceutical…
Read More...

CStone Pharmaceuticals announced that the company has entered into a global clinical collaboration with China focus with Bayer HealthCare LLC to evaluate the safety, tolerability,…
Read More...

Biogen announced that it has completed its acquisition of Nightstar Therapeutics, a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for…
Read More...

Bayer and Arvinas, a biopharmaceutical company creating a new class of therapies to degrade disease-causing proteins, announced an agreement to leverage Arvinas’ novel PROTAC protein…
Read More...

Celgene Corporation and Acceleron Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an…
Read More...